Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis
暂无分享,去创建一个
P. Hematti | M. Mushtaq | F. Lutfi | N. Ahmed | S. G. Chaudhary | Iqra Anwar | A. Hussain | M. Faisal | M. Shahzad | J. Mcguirk | Nausheen Ahmed | E. Tariq | Andy Nguyen | Fatima Ali | Anurag K. Singh | Mohammad Ammad-ud-din | Atif Butt
[1] W. Wilson,et al. CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How? , 2021, The New England journal of medicine.
[2] M. Chartrand,et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients , 2021, Stem cell research & therapy.
[3] Hua Jiang,et al. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia , 2021, Clinical Cancer Research.
[4] C. Turtle,et al. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success , 2021, BioDrugs.
[5] Depei Wu,et al. Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia. , 2021, Molecular medicine reports.
[6] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[7] H. Einsele,et al. Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML. , 2021, Blood.
[8] S. Ferrone,et al. Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia , 2021, Clinical Cancer Research.
[9] Sophie Curio,et al. A summary of current NKG2D-based CAR clinical trials , 2021, Immunotherapy advances.
[10] Depei Wu,et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation , 2020, Journal of Hematology & Oncology.
[11] S. Jagannath,et al. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma , 2020 .
[12] G. Marcucci,et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] M. Tallman,et al. How I Treat Relapsed or Refractory AML. , 2020, Blood.
[14] M. Horowitz,et al. The Changing Landscape of Treatment in Acute Myeloid Leukemia. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[15] S. Gottschalk,et al. A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy , 2020, Frontiers in Oncology.
[16] C. June,et al. Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. , 2020, Blood.
[17] A. Mims,et al. Relapsed or primary refractory AML: moving past MEC and FLAG-ida , 2020, Current opinion in hematology.
[18] S. Yao,et al. Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML , 2019, Front. Oncol..
[19] S. Gill,et al. Will CAR T cell therapy have a role in AML? Promises and pitfalls. , 2019, Seminars in hematology.
[20] Depei Wu,et al. Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells , 2019, Bone Marrow Transplantation.
[21] D. Neuberg,et al. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma , 2018, Cancer Immunology Research.
[22] H. Ren,et al. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia]. , 2018, Zhonghua nei ke za zhi.
[23] S. Agaugué,et al. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient , 2018, Haematologica.
[24] B. Polić,et al. NKG2D: A Master Regulator of Immune Cell Responsiveness , 2018, Front. Immunol..
[25] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[26] Depei Wu,et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. , 2018, American journal of cancer research.
[27] Hong Wang,et al. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. , 2017, Cytotherapy.
[28] S. Rosenberg,et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] He Huang,et al. First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia , 2015 .
[30] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[31] Quan-shun Wang,et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] R. Walter. The role of CD33 as therapeutic target in acute myeloid leukemia , 2014, Expert opinion on therapeutic targets.
[33] Angel F. Lopez,et al. Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor , 2013, British journal of haematology.
[34] D. Powell,et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. , 2012, Blood.
[35] Hisashi Sakamaki,et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.
[36] David D. Smith,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.